Vitrase “approvable”
Executive Summary
Allergan/ISTA Vitrase "approvable" for vitreous hemorrhage treatment (ovine hyaluronidase), FDA letter says. "FDA requested additional analysis of the existing data and an additional confirmatory clinical study based upon that analysis," ISTA said. FDA's Dermatologic & Ophthalmic Drugs Advisory Committee determined in March that existing data did not demonstrate efficacy, but said ISTA could analyze subgroups and effects on vision for further evidence of efficacy (1"The Pink Sheet" March 24, p. 33). "FDA also cited issues related to the drug substance and drug specifications," company said. FDA did not note any deficiencies in safety data, ISTA added...
You may also be interested in...
ISTA Vitrase Data Subgroup Analysis Could Support Efficacy, Cmte. Says
A subgroup analysis of Allergan/ISTA's Vitrase data could provide additional evidence for efficacy of the ophthalmic drug for treatment of vitreous hemorrhage, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee said March 17
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.